Why So Late?!--delay in Treatment of Colorectal Cancer is Socially Determined
Overview
Affiliations
Purpose: The interval between symptom onset and therapy in patients with colorectal cancer was studied.
Methods: One hundred twenty three patients with colorectal cancer were included. Demography data, symptoms, consultations, and tumour stage were obtained by standardized questionnaires. Risk factors for delayed treatment were analysed.
Results: Eighty six patients suffered from colonic cancer. The total time between the first symptoms and therapy ranged from 13 to 442 days (mean, 148). Delay of surgical therapy was responsible for significantly higher tumour grades. Delayed start of therapy was found to be correlated to the type of cancer, socioeconomic status, marital status, and quality of first consultation (univariate analysis). On multivariate analyses, type of cancer, marital and socioeconomic status remained significantly associated with delayed treatment (all p values ≤ 0.001, r(2) = 0.50).
Conclusions: The delay in treatment of colorectal cancer depends on socioeconomic status and family background. Achieving equity in colorectal cancer detection may require consideration of high-risk subgroups.
Ling S, Luque Fernandez M, Quaresma M, Belot A, Rachet B Br J Cancer. 2023; 130(1):88-98.
PMID: 37741899 PMC: 10781675. DOI: 10.1038/s41416-023-02440-6.
Conflicting Guidelines: A Systematic Review on the Proper Interval for Colorectal Cancer Treatment.
Molenaar C, Janssen L, van der Peet D, Winter D, Roumen R, Slooter G World J Surg. 2021; 45(7):2235-2250.
PMID: 33813632 DOI: 10.1007/s00268-021-06075-7.
Pre-to-post diagnosis weight trajectories in colorectal cancer patients with non-metastatic disease.
van Zutphen M, Geelen A, Boshuizen H, Winkels R, Geijsen A, Wesselink E Support Care Cancer. 2018; 27(4):1541-1549.
PMID: 30484014 PMC: 6394719. DOI: 10.1007/s00520-018-4560-z.
Weber D, Amar L, Godde D, Prinz C Oncotarget. 2018; 9(43):27256-27267.
PMID: 29930763 PMC: 6007480. DOI: 10.18632/oncotarget.25535.
Socioeconomic disparities affect survival in malignant ovarian germ cell tumors in AYA population.
Bownes L, Stafman L, Maizlin I, Dellinger M, Gow K, Goldin A J Surg Res. 2017; 222:180-186.e3.
PMID: 28988685 PMC: 5742061. DOI: 10.1016/j.jss.2017.09.013.